These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24031027)

  • 1. PD-1 blockage delays murine squamous cell carcinoma development.
    Belai EB; de Oliveira CE; Gasparoto TH; Ramos RN; Torres SA; Garlet GP; Cavassani KA; Silva JS; Campanelli AP
    Carcinogenesis; 2014 Feb; 35(2):424-31. PubMed ID: 24031027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
    Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
    Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD25+ T cell depletion impairs murine squamous cell carcinoma development via modulation of antitumor immune responses.
    Ramos RN; Oliveira CE; Gasparoto TH; Malaspina TS; Belai EB; Cavassani KA; Garlet GP; Silva JS; Campanelli AP
    Carcinogenesis; 2012 Apr; 33(4):902-9. PubMed ID: 22345289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
    Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
    Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation.
    Liu L; Zheng Q; Lee J; Ma Z; Zhu Q; Wang Z
    J Cell Mol Med; 2015 Jun; 19(6):1223-33. PubMed ID: 25810125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation.
    Currie AJ; Prosser A; McDonnell A; Cleaver AL; Robinson BW; Freeman GJ; van der Most RG
    J Immunol; 2009 Dec; 183(12):7898-908. PubMed ID: 20007574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
    Azpilikueta A; Agorreta J; Labiano S; Pérez-Gracia JL; Sánchez-Paulete AR; Aznar MA; Ajona D; Gil-Bazo I; Larrayoz M; Teijeira A; Rodriguez-Ruiz ME; Pio R; Montuenga LM; Melero I
    J Thorac Oncol; 2016 Apr; 11(4):524-36. PubMed ID: 26845193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
    Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
    Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice.
    Kasagi S; Kawano S; Okazaki T; Honjo T; Morinobu A; Hatachi S; Shimatani K; Tanaka Y; Minato N; Kumagai S
    J Immunol; 2010 Mar; 184(5):2337-47. PubMed ID: 20139271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer.
    Saito H; Kuroda H; Matsunaga T; Osaki T; Ikeguchi M
    J Surg Oncol; 2013 Apr; 107(5):517-22. PubMed ID: 23129549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model.
    Tzeng HT; Tsai HF; Liao HJ; Lin YJ; Chen L; Chen PJ; Hsu PN
    PLoS One; 2012; 7(6):e39179. PubMed ID: 22761734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV.
    Fisicaro P; Valdatta C; Massari M; Loggi E; Ravanetti L; Urbani S; Giuberti T; Cavalli A; Vandelli C; Andreone P; Missale G; Ferrari C
    Gastroenterology; 2012 Dec; 143(6):1576-1585.e4. PubMed ID: 22929808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
    Prosser ME; Brown CE; Shami AF; Forman SJ; Jensen MC
    Mol Immunol; 2012 Jul; 51(3-4):263-72. PubMed ID: 22503210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
    Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
    Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8⁺ T cells.
    Kaiser AD; Schuster K; Gadiot J; Borkner L; Daebritz H; Schmitt C; Andreesen R; Blank C
    Eur J Immunol; 2012 Mar; 42(3):662-71. PubMed ID: 22144176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions.
    Sugita S; Usui Y; Horie S; Futagami Y; Aburatani H; Okazaki T; Honjo T; Takeuchi M; Mochizuki M
    Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2862-70. PubMed ID: 19182257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions.
    Iwamura K; Kato T; Miyahara Y; Naota H; Mineno J; Ikeda H; Shiku H
    Gene Ther; 2012 Oct; 19(10):959-66. PubMed ID: 22113316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of programmed death receptor-1 signaling restores expression of mostly proinflammatory cytokines in anergic cytomegalovirus-specific T cells.
    Dirks J; Egli A; Sester U; Sester M; Hirsch HH
    Transpl Infect Dis; 2013 Feb; 15(1):79-89. PubMed ID: 23176118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
    Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
    J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.